The Henry Ford Health System has been granted a patent for methods to prevent and treat cardiovascular diseases in patients with cerebrovascular injuries. The patent involves administering agents containing microRNA-126. GlobalData’s report on Henry Ford Health System gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Henry Ford Health System, was a key innovation area identified from patents. Henry Ford Health System's grant share as of May 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of cardiovascular disorders with microrna-126 in diabetic stroke patients
A recently granted patent (Publication Number: US11957705B2) discloses a method for treating cardiovascular disorders or diseases in subjects with Type 2 Diabetes Mellitus who have suffered a stroke. The method involves administering exosomes containing miR-126, with the exosomes derived from CD133+ cells, specifically CD133+/KDR+ cells isolated from human umbilical cord blood cells. The concentration of miR-126 in these exosomes is highlighted as being higher than that found in exosomes from endothelial cells or human umbilical cord blood cells.
Furthermore, the patent claims that the exosomes may also contain miR-29b in addition to miR-126, with the concentration of miR-29b in these exosomes being greater than that in exosomes derived from endothelial cells or human umbilical cord blood cells. The therapeutic amount of exosomes administered is specified to be at least 3×1010, and the method is applicable to treating ischemic or hemorrhagic strokes, as well as heart failure and cardiomyopathy, particularly systolic heart failure with a left ventricle ejection fraction of less than 40%. The patent also mentions the derivation of exosomes from endothelial cells, specifically brain endothelial cells, for this treatment method.
To know more about GlobalData’s detailed insights on Henry Ford Health System, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
